Autolus Therapeutics to Participate in Investor Conferences Through April

Rhea-AI Summary

Autolus Therapeutics plc (Nasdaq: AUTL) announced participation in several investor conferences throughout April 2021. Key events include the Wells Fargo Annual Biotech Corporate Access on April 6 and 8, and the 20th Annual Needham Virtual Healthcare Conference on April 14, where the CEO and CFO will engage in a Fireside Chat. Additionally, Autolus will partake in the Raymond James Oncology Summit on April 22 and Kempen & Co. European Life Sciences: Gene, Cell, and RNA Day on April 28. This participation highlights Autolus's commitment to advancing its next-generation T cell therapies for cancer treatment.

News Market Reaction – AUTL

+1.02%

+1.02% Session move

In the trading session that priced this news, AUTL gained 1.02%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in 1x1’s at investor conferences through April 2021.

• April 6 and 8, 2021 - Wells Fargo Annual Biotech Corporate Access
• April 14, 2021 - 20th Annual Needham Virtual Healthcare Conference – As well as 1x1’s, the CEO and CFO will participate in a Fireside Chat at 10:15 AM ET. A webcast of the Fireside Chat will be available on the investor relations section of the Company’s website at Autolus.
• April 22, 2021 - Raymond James Oncology Summit
• April 28, 2021 - Kempen & Co. European Life Sciences: Gene, Cell, and RNA Day

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.

Contact:

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com

FAQ

What events will Autolus Therapeutics participate in during April 2021?

Autolus Therapeutics will participate in the Wells Fargo Annual Biotech Corporate Access on April 6 and 8, the 20th Annual Needham Virtual Healthcare Conference on April 14, the Raymond James Oncology Summit on April 22, and the Kempen & Co. European Life Sciences: Gene, Cell, and RNA Day on April 28, 2021.

Will there be a Fireside Chat featuring Autolus Therapeutics management?

Yes, there will be a Fireside Chat with the CEO and CFO of Autolus Therapeutics at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 10:15 AM ET.

Where can I watch the Autolus Therapeutics Fireside Chat?

The Fireside Chat will be available via webcast on the investor relations section of Autolus Therapeutics' website.

What is Autolus Therapeutics focusing on in their pipeline?

Autolus Therapeutics is developing next-generation programmed T cell therapies aimed at treating hematological malignancies and solid tumors.